Taiwan's ScinoPharm forges link for biosimilars production with US firm
This article was originally published in Scrip
Taiwan's ScinoPharm is to make an investment in the US firm Tanvex Biologics, with the intention of building up joint capacity for the manufacture of biosimilars in the US market.
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker.
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.
US venture raises new funds from Asia partners as it builds a direct presence in China to develop its oncology portfolio.